SCIENTIFIC POSTER_Katarzyna Michalska-Malecka


The purpose of this study was to evaluate the effectiveness of series of oral low-dose methotrexate for the treatment of chronic central serous chorioretinopathy (CSCR).


This prospective, comparative clinical study included six eyes of 6 patients with symptomatic CSCR who were observed at the Department of Ophthalmology, University Centre of Ophthalmology and Oncology, Medical University of Silesia in Katowice. Patients were diagnosed with CSCR based on history, physical examination, macular optical coherence tomography, and intravenosus fluorescein angiography results (the presence of leakage). Our patients were treated with oral low-dosage methotrexate (7.5 mg per week) along with folic acid supplementation (5 mg per week). Patients were monitored with monthly complete blood count and comprehensive metabolic panel. The outcome measures included best-corrected visual acuity (BCVA), central macular thickness and total volume of the retina measurement with optical coherence tomography (OCT) as well as changes in fluorescein angiography. The same OCT machine was used for each patient throughout the study (3D OCT 2000 Topcon).


The mean age of the patients was 48.2 ± 5.3 years. The study was based on analysis of 3 women and 3 men. The mean duration of treatment was 61 days. Mean best-corrected visual acuity increased by 2 ± 2 lines. Mean central macular thickness standard deviation decreased from 367.5 ± 129.9 microns to 327.5 ± 130.4 microns. Mean total macular volume improved from 10 to 8.37. Leakage on fluorescein angiography decreased in conjunction with improvement in central macular thickness observed by OCT. No MTX-associated toxicity was evident. The results of our research will be subjected to statistical analysis.


Oral low-dosage methotrexate resulted in improved visual acuity and anatomical results for CSCR. MTX therapy seems to be a potentially attractive option for patients who are not good candidates for other methods of treatment including surgical interventions. Continued studies in this population are warranted to evaluate the long-term safety and efficacy of oral low-dosage methotrexate.